The Dana-Farber/Harvard Cancer Center Prostate Cancer Program is a scientifically broad-based multidisciplinary program connecting 81 members from all seven DF/HCC institutions of the consortium and ten departments of HMS and two departments of HSPH. The Program is led by P. Kantoff(DFCI). It is co-led by two clinical investigators: M. Sanda(BIDMC) and M. Smith (MGH). The leadership has created a nurturing environment for established and junior investigators alike and a productive environment within which interdisciplinary collaborations among basic, translational, and clinical investigators can occur. The expertise within the Program is broad, and the high caliber of the clinicians, basic scientists, translational scientists and population scientists makes for a richly interactive community for collaboration. Program members have published 899 reports in peer-reviewed journals over the past five years, of which 19% were intra-programmatic, 39% inter-programmatic, and 28% inter-institutional. Member funding in the area of prostate cancertotals more than $23.6 million in calendar year 2009, including $13.3 million from the NCI and $4.8 million from other peer-reviewed sponsors. The Program has been approved and funded by the CCSG since the founding of DF/HCC. At the time of the last CCSG renewal, the Prostate Cancer Program received an Excellent merit score.
The Specific Aims of the Prostate Cancer Program are to: 1. Define and characterize germline genetic variations, somatic mutations as well as environmental factors leading to the pathogenesis and identification of "aggressive" prostate cancer. 2. Develop a better understanding of androgen signaling and develop therapies directed at this pathway while minimizing side effects. 3. Improve prostate cancer treatment through better use of individual clinical and molecular characteristics to select or refine treatment, and by the introduction of genetically-based and other novel therapeutic strategies.

Public Health Relevance

Prostate cancer is the leading cause of cancer and the second leading cause of cancer mortality in men in the United States. The DF/HCC Prostate Cancer Program seeks to understand the pathogenesis and mechanisms of disease progression, to identify which men have aggressive prostate cancer and need to be treated, and to determine what constitutes optimal treatment for men with localized as well as advanced disease.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Dana-Farber Cancer Institute
United States
Zip Code
Chen, Yi-Bin; Batchelor, Tracy; Li, Shuli et al. (2015) Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma. Cancer 121:226-33
Waldron, Levi; Haibe-Kains, Benjamin; Culhane, Aedín C et al. (2014) Comparative meta-analysis of prognostic gene signatures for late-stage ovarian cancer. J Natl Cancer Inst 106:
Yilmazel, Bahar; Hu, Yanhui; Sigoillot, Frederic et al. (2014) Online GESS: prediction of miRNA-like off-target effects in large-scale RNAi screen data by seed region analysis. BMC Bioinformatics 15:192
Mazzola, Emanuele; Chipman, Jonathan; Cheng, Su-Chun et al. (2014) Recent BRCAPRO upgrades significantly improve calibration. Cancer Epidemiol Biomarkers Prev 23:1689-95
Zhao, Sihai Dave; Parmigiani, Giovanni; Huttenhower, Curtis et al. (2014) Más-o-menos: a simple sign averaging method for discrimination in genomic data analysis. Bioinformatics 30:3062-9
Parkhitko, Andrey A; Priolo, Carmen; Coloff, Jonathan L et al. (2014) Autophagy-dependent metabolic reprogramming sensitizes TSC2-deficient cells to the antimetabolite 6-aminonicotinamide. Mol Cancer Res 12:48-57
Cheng, Long; Desai, Jigar; Miranda, Carlos J et al. (2014) Human CFEOM1 mutations attenuate KIF21A autoinhibition and cause oculomotor axon stalling. Neuron 82:334-49
Akbay, Esra A; Moslehi, Javid; Christensen, Camilla L et al. (2014) D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. Genes Dev 28:479-90
Brunner, Andrew M; Blonquist, Traci M; Sadrzadeh, Hossein et al. (2014) Population-based disparities in survival among patients with core-binding factor acute myeloid leukemia: a SEER database analysis. Leuk Res 38:773-80
Karamichos, D; Hutcheon, A E K; Rich, C B et al. (2014) In vitro model suggests oxidative stress involved in keratoconus disease. Sci Rep 4:4608

Showing the most recent 10 out of 177 publications